Vali Barsan

Vali Barsan is an Attending Physician in Oncology at Stanford University School of Medicine, with clinical expertise in leukemia and lymphoma, molecular diagnostics for relapsed cancers, and cancer immunotherapy Phase I trials. In addition, Vali serves as an Instructor in Pediatric Hematology/Oncology and Stem Cell Transplantation. Vali's research interests include molecular monitoring and in vivo immune and stem cell lineage tracing. Vali is also a founding team member and Clinical Fellow at Kamau Therapeutics, Board Director for multiple companies including ArsenalBio, Neuron23, Umoja Biopharma, and Karius, focusing on innovative approaches in cancer immunotherapy and precision medicine. Prior experience includes roles at Illumina as a Medical Consultant, where Vali specialized in next-generation sequencing for cancer diagnostics, and a research position at MD Anderson Cancer Center, focusing on circulating tumor cells. Vali holds advanced degrees from esteemed institutions, including an M.D. from Baylor College of Medicine and a fellowship from Stanford University School of Medicine.